The hemodynamic effects of Warfarin on posttraumatic pulmonary embolism patients
10.3969/j.issn.1671-8348.2013.36.020
- VernacularTitle:华法林对创伤性肺栓塞患者血流动力学的影响
- Author:
Yang LIU
- Publication Type:Journal Article
- Keywords:
hemodynamics;
pulmonary embolism;
warfarin;
trauma
- From:
Chongqing Medicine
2013;(36):4412-4414
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the impact of Warfarin on posttraumatic pulmonary embolism patients .Methods 40 cases of posttraumatic pulmonary embolism patients from June 2008 to September 2012 in this hospital were collected as the treatment group ,40 healthy volunteers were chosen as the control group at the same time .Warfarin anticoagulant therapy was used for the treatment group ,no treatment was used in the control group .Monitoring the hemodynamic parameters of the treatment group at the time point of before treatment and 15 ,30 ,45 ,90 h after treatment .After treatment ,the hemodynamic parameters of the control group were used as control .Results Mean arterial pressure (MAP) ,cardiac index (CI) ,stroke volume (SV) ,stroke index (SI) and pulmonary artery wedge pressure (PAWP) of the treatment group were significantly lower than the control group before treatment with statistical significance (P<0 .05) .Heart rate (HR) ,systemic vascular resistance (SVR) ,pleural hydrostatic pressure (TFC) and pulmonary vascular resistance (PVR) were significantly higher that of control group ,with statistical significance (P<0 .05) . Before 45 h after the treatment ,MAP ,CI ,SV and SI of the treatment group were still significantly lower than the control group (P<0 .05) ,however ,there were no statistically difference after 90 h except PAWP (P>0 .05) .HR ,SVR and TFC of the treatment group were significantly higher than control after 90 h ,however ,the difference was not statistically significant of PVR in two groups .Conclusion Monitoring the hemodynamic changes during the treatment by Warfarin in posttraumatic pulmonary embolism patients can provide an important basis for the assessment and treatment of these diseases .
